Chapter 4

Blood-brain barrier P-glycoprotein function in Alzheimer’s disease

Daniëlle M.E. van Assema1,2, Mark Lubberink1,3, Martin Bauer4, Wiesje M. van der Flier2, Robert C. Schuit1, Albert D. Windhorst1, Emile F.I. Comans1, Nikie J. Hoetjes1, Nelleke Tolboom1, Oliver Langer4, Markus Müller4, Philip Scheltens2, Adriaan A. Lammertsma1, Bart N.M. van Berckel1

1 Department of Nuclear Medicine & PET Research, VU University Medical Center, Amsterdam, The Netherlands
2 Department of Neurology & Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
3 PET Centre, Uppsala University Hospital, Uppsala, Sweden
4 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria


**ABSTRACT**

A major pathological hallmark of Alzheimer’s disease is accumulation of amyloid-β in senile plaques in the brain. Evidence is accumulating that decreased clearance of amyloid-β from the brain may lead to these elevated amyloid-β levels. One of the clearance pathways of amyloid-β is transport across the blood-brain barrier via efflux transporters. P-glycoprotein, an efflux pump highly expressed at the endothelial cells of the blood-brain barrier, has been shown to transport amyloid-β. P-glycoprotein function can be assessed *in vivo* using $(R)$-[¹¹C]verapamil and positron emission tomography. The aim of this study was to assess blood-brain barrier P-glycoprotein function in Alzheimer’s disease patients compared with age matched healthy controls using $(R)$-[¹¹C]verapamil and positron emission tomography. In 13 Alzheimer’s disease patients (age 65 ± 7, Mini-Mental State Examination 23 ± 3) global $(R)$-[¹¹C]verapamil binding potential values were increased significantly ($p = 0.001$) compared with 14 healthy controls (age 62 ± 4, Mini-Mental State Examination 30 ± 1). Global $(R)$-[¹¹C]verapamil binding potential values were 2.18 ± 0.25 for Alzheimer’s disease patients and 1.77 ± 0.41 for healthy controls. In AD patients, higher $(R)$-[¹¹C]verapamil binding potential values were found for frontal, parietal, temporal and occipital cortices, and posterior and anterior cingulate. No significant differences between groups were found for medial temporal lobe and cerebellum.

These data show altered kinetics of $(R)$-[¹¹C]verapamil in Alzheimer’s disease, similar to alterations seen in studies where P-glycoprotein is blocked by a pharmacological agent. As such, these data indicate that P-glycoprotein function is decreased in patients with Alzheimer’s disease. This is the first direct evidence that the P-glycoprotein transporter at the blood-brain barrier is compromised in sporadic Alzheimer’s disease and suggests that decreased P-glycoprotein function may be involved in the pathogenesis of Alzheimer’s disease.
INTRODUCTION

Alzheimer’s disease (AD) is the most common form of dementia [1]. A major pathological hallmark of AD is the deposition of amyloid-β plaques in the brain [2]. Amyloid-β pathology can be visualized and quantified in vivo using [11C]Pittsburgh compound B (PIB) and PET [3-4].

The origin of amyloid-β depositions in Alzheimer’s disease is unclear. The amyloid hypothesis proposes that this may be caused by an imbalance between amyloid-β production and clearance [5-6]. In familial Alzheimer’s disease, which accounts for <5% percent of all cases, there is evidence of life-long increased production of amyloid-β due to genetic alterations [6]. In the far more common sporadic Alzheimer’s disease, however, especially a failure to clear amyloid-β from the brain is thought to play an important role in the pathogenesis of the disease [7]. Mechanisms involved in clearing amyloid-β from the brain include degradation by a variety of proteases, removal through the interstitial fluid-CSF bulk flow into the bloodstream, perivascular lymphatic drainage and transport across the blood-brain barrier [8]. Although the exact cause of reduced clearance of amyloid-β from the brain in sporadic Alzheimer’s disease remains unclear, several leads point towards a regulatory role for the blood-brain barrier [9-10].

The blood-brain barrier, composed of a monolayer of brain capillary endothelial cells, serves to maintain homeostasis in the CNS and protects the brain from toxic substances. These blood-brain barrier functions are realized through different mechanisms, such as tight junctions between adjacent endothelial cells to prevent entry of compounds into the brain, and active efflux mechanisms to transport endogenous and exogenous substances from brain to blood [11]. Due to the presence of tight junctions between cerebrovascular endothelial cells, the transport of amyloid-β across the blood-brain barrier requires carrier- or receptor-mediated transport systems. The receptor for advanced glycation end products is a primary transporter of amyloid-β from the systemic circulation across the blood-brain barrier into the brain, whereas the low-density lipoprotein receptor-related protein-1 (LRP1) is one of the transporters involved in the transport of amyloid-β out of the brain [12-14].

Recently, it has been suggested that P-glycoprotein, a 170 kDa plasma membrane protein encoded in humans by the multi-drug resistance 1 gene (MDR1 or ABCB1) and belonging to the family of ATP-binding cassette transporters, is also involved in the clearance of amyloid-β from brain. P-glycoprotein is expressed in organs with an excretory and/or barrier function, such as intestine, liver, kidney and the blood-brain barrier. At the blood-brain barrier, P-glycoprotein is highly expressed at the luminal side of the endothelial cells [15], where it acts as an efflux transporter, extruding substances from the brain to the blood [16-17]. Being able to transport a broad spectrum of substrates, P-glycoprotein has been shown to play an important role in maintaining homeostasis in the CNS, thereby protecting the brain from accumulation of potentially toxic substances [18-19].
The evidence that amyloid-β is also a substrate for P-glycoprotein is based on several studies. For instance, it has been shown in vitro that P-glycoprotein transports amyloid-β and that blocking P-glycoprotein function decreases transport of amyloid-β [20-21]. Furthermore, amyloid-β depositions are inversely correlated with P-glycoprotein expression in the brain of elderly nondemented humans [22]. In addition, in an Alzheimer’s disease mouse model, knocking out blood-brain barrier P-glycoprotein expression increased amyloid-β depositions [23], whilst restoring blood-brain barrier P-glycoprotein expression and transport activity reduced brain amyloid-β levels [24]. At present, there is no in vivo information on P-glycoprotein function in sporadic Alzheimer’s disease.

P-glycoprotein function can be assessed in vivo using the PET tracer [11C]verapamil [25-27]. [11C]verapamil enters the brain through passive diffusion and, at the low concentrations used in PET, it is a substrate for P-glycoprotein [28-29]. The validity of [11C]verapamil as a PET tracer for assessing P-glycoprotein function was further demonstrated by increased cerebral retention of [11C]verapamil following blockade of P-glycoprotein with cyclosporine [30-31]. [11C]verapamil has often been used in its racemic form, as both (R) and (S) enantiomers are substrates for P-glycoprotein. Nevertheless, for quantification of P-glycoprotein function a pure enantiomer is required. As (R)-[11C]verapamil is less metabolized in the human body than (S)-[11C]verapamil, it is considered to be the preferred isomer [32] and the brain retention of (R)-[11C]verapamil is thought to be inversely related to blood-brain barrier P-glycoprotein function. Using [11C]verapamil and PET, it has been shown that blood-brain barrier P-glycoprotein function decreases in normal ageing and in neurodegenerative diseases such as progressive supranuclear palsy and multiple system atrophy, with conflicting results in Parkinson’s disease [33-37]. As decreased clearance of amyloid-β from the brain is thought to be a major cause of amyloid-β accumulation in the pathogenesis of sporadic Alzheimer’s disease, together with the fact that P-glycoprotein is able to transport amyloid-β, the purpose of this study was to measure blood-brain barrier P-glycoprotein function in vivo using (R)-[11C]verapamil PET in patients with sporadic Alzheimer’s disease and healthy controls. The hypothesis was that P-glycoprotein function is reduced in patients with Alzheimer’s disease, so that an increase in binding potential (BPND) of (R)-[11C]verapamil is expected in patients with Alzheimer’s disease compared with healthy controls.

MATERIALS AND METHODS

Participants
Fifteen subjects with probable Alzheimer’s disease and fourteen age-matched healthy controls were included in this study. Patients with Alzheimer’s disease with mild to moderate disease (Mini-Mental State Examination scores ≥20 [38]) were recruited from the out-patient Memory Clinic of the Alzheimer Center of the VU University Medical Center, Amsterdam. All
subjects received a standard dementia screening that included medical history, physical and neurological examinations, screening laboratory tests, and brain MRI. Clinical diagnosis of probable Alzheimer’s disease was established by consensus in a multidisciplinary meeting according to the criteria proposed by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) [39]. To confirm the presence of Alzheimer’s disease pathology in the brain, increased cortical accumulation of $[^11]C$PIB PET was required for patients with Alzheimer’s disease [40]. Controls were recruited by means of flyers and through advertisements in newspapers. Controls had normal cognitive function with normal Mini-Mental State Examination scores (>26). Exclusion criteria for all participants were history of any major psychiatric or neurological illness (other than Alzheimer’s disease). None of the healthy controls used medication. Five of the patients with Alzheimer’s disease were being treated with acetylcholinesterase inhibitors. Acetylcholinesterase inhibitors are not known to be transported by P-glycoprotein or interfere with P-glycoprotein function [41-42]. Two patients with Alzheimer’s disease were on low doses of antidepressant medication, which possibly are substrates for P-glycoprotein [43-44], one patient using citalopram 20 mg/day, the other nortriptyline 10 mg/day. Additional exclusion criteria for controls were subjective memory complaints or clinically significant abnormalities on brain MRI as determined by a neuroradiologist. The study was approved by the Medical Ethics Review Committee of the VU University Medical Center. Written informed consent was obtained from all subjects after a complete written and verbal description of the study.

**Magnetic resonance imaging**

All subjects underwent structural MRI using a 1.5 T Sonata scanner (Siemens Medical Solutions), except four of the healthy male subjects who were scanned using a 1.0 T Magnetom Impact scanner (Siemens Medical Solutions). The scan protocol on both MRI scanners was identical and included a coronal T1-weighted 3-D MPRAGE (magnetization prepared rapid acquisition gradient echo; slice thickness 1.5 mm, 160 slices, matrix size 256 x 256; voxel size of 1 x 1 x 1.5 mm; echo time = 3.97 ms; repetition time = 2.700 ms; inversion time = 950 ms; flip angle 8°), which was used for co-registration and region of interest definition.

**Positron emission tomography data acquisition**

PET scans were performed on an ECAT EXACT HR+ scanner (Siemens/CTI), equipped with a neuro-insert to reduce the contribution from outside field of view activity. This scanner enables the acquisition of 63 transaxial planes over a 15.5 cm axial FOV, allowing the whole brain to be imaged in a single bed position. The properties of this scanner have been reported elsewhere [45]. All subjects received an indwelling radial artery cannula for arterial blood sampling and a venous cannula for tracer injection. Prior to
tracer injection a 10 min transmission scan in 2D acquisition mode was performed using three retractable rotating ^{68}\text{Ge} rod sources. This scan was used to correct the subsequent emission scan for photon attenuation. Next, a dynamic emission scan in 3D acquisition mode was started simultaneously with a bolus injection of (R)-[^{11}\text{C}]verapamil. The synthesis of (R)-[^{11}\text{C}]verapamil has been described previously [46]. Using an infusion pump (Med-Rad), radiotracer injection was performed at a rate of 0.8 mL/s, followed by a flush of 42 mL saline at 2.0 mL/s. The dynamic emission scan consisted of 20 frames with progressive increase in frame duration (1 x 15, 3 x 5, 3 x 10, 2 x 30, 3 x 60, 2 x 150, 2 x 300, 4 x 600s) and a total duration of 60 min. Patient movement was restricted by the use of a head holder and monitored by checking the position of the head using laser beams. Using an on-line blood sampler (Veenstra Instruments), arterial blood was withdrawn continuously at a rate of 5 mL/min during the first 5 min and 2.5 mL/min during the rest of the scan. At 2.5, 5, 10, 20, 30, 40 and 60 min after tracer injection, continuous blood sampling was interrupted briefly to collect additional manual blood samples. After each sample, the arterial line was flushed with a heparinised saline solution. These manual samples were used to determine plasma to whole blood radioactivity concentration ratios. In addition, fractions of parent (R)-[^{11}\text{C}]verapamil and its radioactive polar metabolites in plasma were determined using a combination of solid-phase extraction and high-pressure liquid chromatography, as described previously [47].

On the same day, patients with Alzheimer’s disease underwent a second PET scan following injection of[^{11}\text{C}]PIB in order to confirm amyloid-β pathology in the brain. This dynamic 90 min scan was acquired as described previously [48].

**Positron emission tomography data analysis**

All PET data were corrected for attenuation, randoms, dead time, scatter and decay. Images were reconstructed using a standard filtered back projection algorithm applying a Hanning filter with a cut-off at 0.5 times the Nyquist frequency. A zoom factor of 2 and a matrix size of 256 x 256 x 63 were used, resulting in a voxel size of 1.2 x 1.2 x 2.4 mm and a spatial resolution of ~6.5 mm full width at half maximum at the centre of the field of view. Co-registration of structural T1-magnetic resonance images to corresponding PET images (using summed images of frames 3 – 12) and segmentation of the co-registered MRI into grey matter, white matter and CSF was performed using statistical parametrical mapping (SPM, version SPM2, www.fil.ion.ucl.ac.uk/spm, Institute of Neurology). Regions of interest were defined based on the segmented MRI using a probabilistic template as implemented in PVElab [49]. PET data were not corrected for partial volume effects. Regions of interest were mapped onto the dynamic PET images and regional time-activity curves were generated. For (R)-[^{11}\text{C}]verapamil scans, the original on-line blood curve was calibrated using whole blood radioactivity concentrations of the seven manual samples. The calibrated whole blood curve was multiplied with a single-exponential fit to the plasma to whole blood ratio,
thereby generating a total plasma curve. Finally, the metabolite corrected plasma input function was obtained by multiplying the total plasma curve with one minus the polar metabolite fraction fitted to a sigmoid function [50].

Kinetic analyses were performed using software developed within Matlab 7.04 (The Mathworks). First, (R)-[11C]verapamil data were analyzed using spectral analysis, a technique that produces a spectrum of the kinetic components that are needed to relate tissue response to plasma input function without making a priori assumptions regarding the number of compartments [51]. This method is based on the assumption that the tissue response to a unit impulse (impulse response function; IRF) can be described as a linear combination of a limited number of pre-defined exponentially decaying basis functions:

$$IRF(t) = \sum \alpha_i \exp(-\beta_i t)$$  

(1)

In the present analysis, 50 basis functions with logarithmically spaced $\beta_i$, ranging from 0.015 to 2 min$^{-1}$ were used. The measured tissue curve $C_T(t)$ is then described as the convolution of IRF($t$) with the plasma input function $C_P(t)$ plus a blood volume term:

$$C_T(t) = \sum \alpha_i C_P(t) \otimes \exp(-\beta_i t) + V_B(t)C_B(t)$$

(2)

Equation 2 can be solved by non-negative least-squares, yielding a limited number of $\alpha_i > 0$, representing the number of tissue compartments necessary to describe the data. For any number of compartments, the parameters $\alpha$ and $\beta$ can be expressed in terms of rate constants of a conventional compartment model with a similar number of compartments, and vice versa.

Based on the results of spectral analysis, (R)-[11C]verapamil data were also analysed using non-linear regression of the standard two tissue compartment model including a blood volume component, yielding, in addition to the individual rate constants ($K_i - k_i$) between compartments, the outcome measure $BP_{ND}$ [52]. $BP_{ND} (= k_3/k_4)$ is the non-displaceable binding potential of verapamil. Starting values for the parameters in the non-linear regression analysis were based on the results of spectral analysis. To obtain robust $BP_{ND}$ values, the non-specific distribution volume $K_1/k_2$ was first determined for a whole brain grey matter region of interest and then assumed to be the same for all grey matter regions of interest [53]. $BP_{ND}$ of frontal (volume-weighted average of orbital frontal, medial inferior frontal, and superior frontal), parietal, temporal (volume-weighted average of superior temporal and medial inferior temporal), occipital, medial temporal lobe (volume-weighted average of entorhinal cortex and hippocampus) and cerebellar cortices and posterior and anterior cingulate was used. In addition, a global cortical region was defined consisting of the volume-weighted average of frontal, parietal, temporal and occipital cortices and anterior and posterior cingulate.
[\textsuperscript{11}C]PIB PET data were analysed as described previously using 90-min dynamic scans [4]. For confirming the presence of amyloid pathology in the brain, [\textsuperscript{11}C]PIB PET scans were assessed visually by an experienced nuclear medicine physician (BvB) and classified as either being PIB-positive or -negative.

In addition to this visual classification, [\textsuperscript{11}C]PIB data were quantified for the same regions of interest as used for the quantitative analysis of \((R)\textsuperscript{-}[\textsuperscript{11}C]\)verapamil data. \(BP_{ND}\) of [\textsuperscript{11}C]PIB was derived for these regions of interest using the simplified reference tissue model (SRTM) [48, 54] with cerebellar grey matter as reference tissue.

**Statistical analysis**

Data are presented as mean ± standard deviation (SD), unless otherwise stated. Group differences were calculated using non-parametric Mann-Whitney U-tests. A \(p<0.05\) was considered significant. The relationship between \(BP_{ND}\) of \((R)\textsuperscript{-}[\textsuperscript{11}C]\)verapamil and \(BP_{ND}\) of [\textsuperscript{11}C]PIB was assessed using Spearman’s correlation coefficient.

**RESULTS**

\((R)\textsuperscript{-}[\textsuperscript{11}C]\)verapamil PET studies were performed in 15 patients with Alzheimer’s disease and 14 healthy controls. [\textsuperscript{11}C]PIB scans were acquired for all patients with Alzheimer’s disease and 3 healthy controls. Of the 15 patients with Alzheimer’s disease, 13 were classified as being PIB positive and 2 as PIB negative. The 2 PIB-negative patients were excluded from the Alzheimer’s disease group for further analysis. Controls who underwent a [\textsuperscript{11}C]PIB scan were PIB negative.

There were no differences between groups with respect to age, sex, injected dose and specific activity of \((R)\textsuperscript{-}[\textsuperscript{11}C]\)verapamil (Table 4.1). As expected, patients with Alzheimer’s disease had significantly lower Mini-Mental State Examination scores than healthy controls.

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>AD</th>
<th>(p) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n)</td>
<td>14</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>62 ± 4</td>
<td>65 ± 7</td>
<td>0.29</td>
</tr>
<tr>
<td>Male/Female (% female)</td>
<td>8/6 (43)</td>
<td>10/3 (23)</td>
<td>0.29</td>
</tr>
<tr>
<td>MMSE</td>
<td>30 ± 1</td>
<td>23 ± 3</td>
<td>&lt;0.000</td>
</tr>
<tr>
<td>Injected dose (MBq)</td>
<td>378 ± 31</td>
<td>354 ± 36</td>
<td>0.10</td>
</tr>
<tr>
<td>Specific activity (GBq/μmol)</td>
<td>40 ± 13</td>
<td>46 ± 29</td>
<td>0.098</td>
</tr>
</tbody>
</table>

Differences between groups were calculated using Mann-Whitney U-tests.

AD: Alzheimer’s disease; MMSE: Mini-Mental State Examination; Injected dose: injected dose of \((R)\textsuperscript{-}[\textsuperscript{11}C]\)verapamil; Specific activity: specific activity of \((R)\textsuperscript{-}[\textsuperscript{11}C]\)verapamil.
Spectral analysis of (R)-[11C]verapamil data clearly showed the presence of two components in both patients with Alzheimer’s disease and healthy controls. In healthy controls these two components had clearance rates of $0.039 \pm 0.010 \text{min}^{-1}$ and $0.43 \pm 0.42 \text{min}^{-1}$ for global cortical region. In patients with Alzheimer’s disease, for global cortical region clearance rates of $0.040 \pm 0.008 \text{min}^{-1}$ and $0.77 \pm 0.49 \text{min}^{-1}$ were found. For the latter component a significantly faster clearance rate was found in Alzheimer’s disease (Figure 4.1, $p=0.0003$). Because of these spectral analysis findings, a two tissue compartment model was implemented and used for further quantitative data analysis.

Figure 4.1 | Results of spectral analysis. Clearance rates on the $x$-axis corresponds to the clearance rates $\beta_i$ of the basis functions in equations 1 and 2, and contribution to $K_i$ on the $y$-axis corresponds to the parameters $a_i$. Lines represent fits of two Gaussian functions through the mean spectrum of all regions of interest from 14 healthy controls (solid line) and 13 patients with Alzheimer’s disease (dashed line).

Table 4.2 | Individual (R)-[11C]verapamil rate constants for the global cortical region.

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>AD</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$k_1$</td>
<td>$0.05 \pm 0.01$</td>
<td>$0.05 \pm 0.01$</td>
<td>0.40</td>
</tr>
<tr>
<td>$k_2$</td>
<td>$0.14 \pm 0.05$</td>
<td>$0.17 \pm 0.03$</td>
<td>0.56</td>
</tr>
<tr>
<td>$k_3$</td>
<td>$0.16 \pm 0.10$</td>
<td>$0.26 \pm 0.08$</td>
<td>0.16</td>
</tr>
<tr>
<td>$k_4$</td>
<td>$0.09 \pm 0.04$</td>
<td>$0.12 \pm 0.03$</td>
<td>0.65</td>
</tr>
</tbody>
</table>

Group differences were calculated using Mann-Whitney U-tests.
AD: Alzheimer’s disease.
For the global cortical region (Table 4.2), no significant differences in rate constants $K_1$, $k_2$, $k_3$, and $k_4$ were found between groups. In addition, rate constants were assessed between groups for frontal, parietal, temporal, occipital, posterior and anterior cingulate, medial temporal lobe and cerebellar regions of interest. For $K_1$, $k_2$ and $k_4$, no significant differences were found between groups. For $k_3$, significant differences were found in posterior cingulate ($p=0.020$) and medial temporal lobe ($p=0.037$) region of interest, with higher values in Alzheimer’s disease compared with healthy controls.

Global cortical $BP_{ND}$ of $(R)$-[11C]verapamil was higher in patients with Alzheimer’s disease compared with age-matched healthy controls (patients with Alzheimer’s disease: $2.18 \pm 0.25$; healthy controls: $1.77 \pm 0.41$, $p=0.001$; Figure 4.2). In fact, for the parietal, temporal, occipital and posterior cingulate region of interest, significantly higher $BP_{ND}$ values were found in Alzheimer’s disease compared with healthy controls. Also for frontal and anterior cingulate region of interest, significantly higher $BP_{ND}$ values were found in Alzheimer’s disease, though the differences for these regions were smaller (Table 4.3). There were no between-group differences for medial temporal lobe and cerebellum. In the two PIB-negative patients, $(R)$-[11C]verapamil $BP_{ND}$ values were in the range of the PIB-positive patients with Alzheimer’s disease with global $BP_{ND}$ values for $(R)$-[11C]verapamil of 2.18 and 2.15, respectively.

No significant associations were found between $BP_{ND}$ of $(R)$-[11C]verapamil and $BP_{ND}$ of [11C]PIB.

**Figure 4.2** | Boxplot for $(R)$-[11C]verapamil $BP_{ND}$ of the global cortical region. The Alzheimer’s disease group (right) shows increased $BP_{ND}$ compared with the healthy control group (left) ($p=0.001$).

$BP_{ND}$: binding potential of $(R)$-[11C]verapamil; AD: Alzheimer’s disease; *: outlier.
P-glycoprotein function in Alzheimer’s disease

Table 4.3  | Binding potential ($BP_{ND}$) of (R)-[11C]verapamil for several cortical brain regions.

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>AD</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td>1.77 ± 0.41</td>
<td>2.18 ± 0.25</td>
<td>0.001</td>
</tr>
<tr>
<td>Frontal</td>
<td>1.79 ± 0.40</td>
<td>2.12 ± 0.28</td>
<td>0.029</td>
</tr>
<tr>
<td>Parietal</td>
<td>1.70 ± 0.37</td>
<td>2.15 ± 0.26</td>
<td>0.000</td>
</tr>
<tr>
<td>Temporal</td>
<td>1.84 ± 0.46</td>
<td>2.29 ± 0.27</td>
<td>0.000</td>
</tr>
<tr>
<td>Occipital</td>
<td>1.75 ± 0.38</td>
<td>2.20 ± 0.25</td>
<td>0.001</td>
</tr>
<tr>
<td>Posterior Cingulate</td>
<td>1.65 ± 0.30</td>
<td>2.20 ± 0.35</td>
<td>0.000</td>
</tr>
<tr>
<td>Anterior Cingulate</td>
<td>1.67 ± 0.50</td>
<td>2.06 ± 0.35</td>
<td>0.029</td>
</tr>
<tr>
<td>Medial Temporal Lobe</td>
<td>2.51 ± 0.79</td>
<td>2.97 ± 0.42</td>
<td>0.120</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>1.87 ± 0.57</td>
<td>1.99 ± 0.24</td>
<td>0.109</td>
</tr>
</tbody>
</table>

Group differences were calculated using Mann-Whitney U-tests.

AD: Alzheimer’s disease.

**DISCUSSION**

The main finding of this study is an increased (R)-[11C]verapamil $BP_{ND}$ in the brain of patients with Alzheimer’s disease as compared with values in healthy age-matched controls. For the global cortical region this increase was ~23% and in some smaller regions like posterior cingulate there was an even larger increase of 33%. This suggests reduced P-glycoprotein function at the blood-brain barrier in patients with Alzheimer’s disease, not only at a regional, but also at a global level. To the best of our knowledge, this is the first in vivo evidence that blood-brain barrier P-glycoprotein transporter dysfunction occurs in sporadic Alzheimer’s disease.

In both patients with Alzheimer’s disease and healthy controls, spectral analysis, a data driven technique, indicated that (R)-[11C]verapamil data were best described using a two compartment model. This is in contrast to a previous study in healthy volunteers, in which a one compartment model was generally preferred, partly because of its superior test-retest variability [55]. In healthy subjects, the need for a second compartment to describe kinetics of (R)-[11C]verapamil is especially evident after blocking P-glycoprotein, for example using cyclosporine-A or tariquidar [56-57]. In the present study, two compartments for (R)-[11C]verapamil were identified, a ‘slow’ compartment and a ‘fast’ compartment. The fast compartment contributes only a few per cent to the total volume of distribution of the tracer. In physiological terms the second compartment is not fully understood. The most logical explanation is that the first compartment represents radiotracer in the vessel wall before it is pumped back into the circulation, whilst the second represents radiotracer retention in the brain parenchyma. If this is the case, $BP_{ND}$ reflects P-glycoprotein function. This is in
line with results of previous studies, where P-glycoprotein inhibition with the very potent
P-glycoprotein inhibitor cyclosporine-A or with tariquidar clearly showed an increase in $k_3$
and, to a lesser extent, in $k_4$, resulting in an overall increase in $BP_{ND}$ [56-57].
As the direction of change in $BP_{ND}$ in the patients with Alzheimer’s disease in this study is
similar to that induced by P-glycoprotein blocking in healthy subjects, the corresponding
increase in $BP_{ND}$ can be interpreted as a measure of decreased P-glycoprotein function.
The pathophysiology underlying decreased P-glycoprotein function at the blood-brain
barrier in Alzheimer’s disease is not known and it is unknown whether P-glycoprotein
function decreases prior to the occurrence of amyloid depositions, or whether amyloid
plaques have a destructive effect on the blood vessel wall resulting in secondary
P-glycoprotein dysfunction. In a post mortem study [58], it was shown that vascular
amyloid-β depositions were never co-localized with expression of P-glycoprotein and that
in brains with early deposition of amyloid-β in arterioles, capillary P-glycoprotein expression
was significantly increased. This suggests that the typically low expression of P-glycoprotein
in arteries and arterioles contributes to local amyloid-β deposition, which in turn results in
compensatory increases in P-glycoprotein expression in capillaries in an attempt to limit
further accumulation. When amyloid-β accumulation increases and capillaries themselves
become amyloidotic and lose their P-glycoprotein, this could lead to further accumulation
of amyloid-β in the brain. Longitudinal in vivo imaging studies of both amyloid deposition
and P-glycoprotein function, preferably in combination with other imaging techniques
to measure the degree of small vessel disease, could shed some light on this interesting
question.

Previously, it has been reported that P-glycoprotein function may play an important role
in the clearance of amyloid-β across the blood-brain barrier [20-24]. As such, decreased
blood-brain barrier P-glycoprotein function may be a crucial factor in the pathogenesis
of Alzheimer’s disease. This is the first study reporting increased (R)-[11C]verapamil $BP_{ND}$
in grey matter in Alzheimer’s disease. This may relate to previous studies with (R)-[11C]
verapamil in healthy ageing, which reported an age-related increase in (R)-[11C]verapamil
retention in white matter regions of the brain [36-37]. (R)-[11C]verapamil $BP_{ND}$ in white
matter was not investigated in the present study, as the tracer kinetic models used have
not been validated for this purpose. Future studies with validated tracers kinetic models for
assessment of white matter P-glycoprotein function should be performed to address the
question whether white matter P-glycoprotein function is changed in Alzheimer’s disease
and to assess it’s relation to grey matter P-glycoprotein function. Furthermore, decreased
P-glycoprotein function may be involved in other diseases where amyloid deposits are
found, such as cerebral amyloid angiopathy, in which amyloid accumulates in blood
vessel walls in the brain [58-59]. Evidence is emerging that Alzheimer’s disease pathology
frequently co-exists and may be associated with cerebrovascular pathology such as cerebral
amyloid angiopathy and arteriosclerotic plaques [59]. Using [11C]PIB PET, it has been shown
that the occipital-to-global $[^{11}\text{C}]$PIB ratio is significantly increased in patients with cerebral amyloid angiopathy, indicating more pronounced amyloid pathology in occipital lobe in patients with cerebral amyloid angiopathy [60]. In the present study increased $B_{\text{ND}}P$ of both $[^{11}\text{C}]$PIB and (R)-$[^{11}\text{C}]$verapamil was found in most large cortical brain regions in patients with Alzheimer’s disease, including the occipital lobe, which supports a possible overlap of Alzheimer’s disease pathology with cerebral amyloid angiopathy pathology.

Probing P-glycoprotein function at the blood-brain barrier in the very early stages of amyloid depositions is of crucial importance. If decreased P-glycoprotein function is involved in the pathogenesis of amyloid deposition in Alzheimer’s disease, this would implicate that P-glycoprotein may be a potential treatment target and a possible target to modulate disease progression. In a broader sense, P-glycoprotein dysfunction in Alzheimer’s disease may be a (surrogate) marker for more widespread blood-brain barrier dysfunction in Alzheimer’s disease, involving also other amyloid-β transporters, such as LRP1.

P-glycoprotein is one of the major efflux pumps at the blood-brain barrier involved in transport out of the brain of various drugs and other toxic compounds [16-17,42]. Consequently, P-glycoprotein dysfunction could make patients with Alzheimer’s disease more vulnerable to drug toxicity and CNS side-effects of drugs that enter the brain. Furthermore, decreased P-glycoprotein function could also lead to accumulation of toxic compounds other than amyloid-β, by which the brain can be damaged even further. Examples of such compounds are environmental toxins like pesticides. Indeed, it has been shown that efflux of the pesticide endosulfan is mediated by P-glycoprotein [61]. This could be an important mechanism underlying neurodegeneration associated with Alzheimer’s disease and other neurodegenerative diseases.

The diagnosis of probable Alzheimer’s disease according to NINCDS-ADRDA criteria is a clinical diagnosis with known sensitivity and specificity of about 65 and 75%, respectively [1]. Therefore, in this study $[^{11}\text{C}]$PIB PET scans were performed to support the clinical diagnosis, in this case leading to the exclusion of two patients from our Alzheimer’s disease sample. (R)-$[^{11}\text{C}]$verapamil $B_{\text{ND}}P$ values in the two patients that were visually classified as PIB negative, were in the range of the PIB-positive patients with Alzheimer’s disease. Quantitatively, however, these two patients did show some amount of increased $[^{11}\text{C}]$PIB binding with RPM2-derived [62] global $[^{11}\text{C}]$PIB $B_{\text{ND}}P$ values of 0.19 and 0.34, respectively. Although this is increased compared with healthy controls, it is still below the threshold of $[^{11}\text{C}]$PIB $B_{\text{ND}}P$ of 0.54 for being $[^{11}\text{C}]$PIB positive [40]. Interestingly, apart from atrophy coherent with Alzheimer’s disease, both patients had significant signs of microvascular pathology on MRI, which by itself is associated with increased $[^{11}\text{C}]$PIB retention [63]: one patient had hallmarks of cerebral amyloid angiopathy, while the other had white matter hyperintensities with beginning confluence of lesions (Fazekas score 2 [64]). As such, it is conceivable that these patients suffer from mixed pathology in the brain and that microvascular pathology may
have contributed to the decreased P-glycoprotein function found in these patients, or vice versa.

No significant correlations were found between $B_{\text{ND}}$ of (R)-[11C]verapamil and $B_{\text{ND}}$ of [11C]PIB. This may be due to a ceiling effect of [11C]PIB, as [11C]PIB uptake appears to behave as an on/off phenomenon in patients with Alzheimer’s disease, [11C]PIB retention does not reflect disease severity [65] and [11C]PIB binding does not increase substantially over time [66]. Furthermore, (R)-[11C]verapamil and [11C]PIB binding showed substantial spatial overlap, although some inconsistencies were also observed. For instance, relatively high [11C]PIB binding was observed in the anterior cingulate and frontal cortex regions of interest, while (R)-[11C]verapamil binding was only moderately increased in these regions. As such, there appears to be a regional distribution in the severity of P-glycoprotein dysfunction in Alzheimer’s disease. Studies in larger samples are necessary to further address these regional differences and its relation to amyloid depositions. To assess whether there is a direct relationship between (R)-[11C]verapamil and [11C]PIB accumulation in future studies, subjects would have to be included at the very early stages of amyloid deposition.

The present results cannot be explained by medication-induced P-glycoprotein blockade, as the present cohort of patients with Alzheimer’s disease did not use medication that is known to interfere with P-glycoprotein function, and there was no use of medication in the control group. Two patients with Alzheimer’s disease used low doses of antidepressant medication, which are P-glycoprotein substrates in mice [43-44]. Theoretically, these compounds could compete with (R)-[11C]verapamil for transport by P-glycoprotein, but exclusion of these patients did not change results (data not shown).

A limitation of this study is the relatively small number of patients with Alzheimer’s disease and controls. There is a need to replicate these findings in larger groups of controls and patients at different stages of the disease. Furthermore, in only 3 of the 14 healthy controls amyloid imaging was performed, which showed no increased [11C]PIB uptake. In post-mortem studies Alzheimer’s disease pathology can be found in ~30% of cognitively healthy elderly subjects and imaging studies also have reported increased [11C]PIB uptake in ~30% of cognitively healthy elderly subjects [67-68]. Therefore, amyloid deposition in some of the remaining 11 controls cannot be excluded. This will, however, not affect the main finding of reduced P-glycoprotein function in patients with Alzheimer’s disease, as inclusion of such healthy controls would tend to reduce the difference between patients with Alzheimer’s disease and controls. In the present study no correction for partial volume effects was applied to the PET data and it is important to note that actual $B_{\text{ND}}$ values could change if a partial volume effect correction would have been performed. However, many uncertainties may affect accuracy and precision of (MRI based) partial volume effect corrections, such as co-registration and segmentation errors, together with the actual MRI scanner and sequence being used [69]. In addition, at present no partial volume effect correction method has been validated for (R)-[11C]verapamil studies. It is expected that atrophy would
result in lower $BP_{ND}$ values of ($R$)-[\(^{11}\)C]verapamil in patients with Alzheimer’s disease due to increased partial volume effects in this group. Therefore, the actual increase of ($R$)-[\(^{11}\)C]verapamil accumulation in Alzheimer’s disease may have been underestimated.

The strength of this study is that it is the first to directly compare patients with Alzheimer’s disease with healthy age-matched controls with the P-glycoprotein substrate tracer ($R$)-[\(^{11}\)C]verapamil. Dynamic PET studies were performed with arterial blood sampling and full kinetic modelling, providing quantitative data on P-glycoprotein function in patients with Alzheimer’s disease with confirmed amyloid pathology and healthy controls. Results strongly suggest decreased P-glycoprotein function in Alzheimer’s disease.

**Acknowledgements**

We would like to thank the technology staff of the Department of Nuclear Medicine and PET Research for their help with the acquisition of PET data and the technology staff of the Department of Radiology for acquisition of MRI data.

This work was supported by the Alzheimer’s Association (grant number NIRG-07-59545) and Amsterdam Brain Imaging Project (ABIP, grant number 2006-06). In addition the research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013, under grant agreement nº 201380).
REFERENCES


